Reporting HER2 IHC in 2026: CAP-Aligned Reporting Across Tumor Types and the Impact of Intratumoral Heterogeneity

REFINING HER2 IHC ASSESSMENT GUIDED BY CAP REPORTING TEMPLATE: ENABLING ACCURATE CLASSIFICATION ACROSS SOLID TUMORS AND ADDRESSING INTRATUMORAL HETEROGENEITY

/in , , , , , /by

The use of IHC staining of tissue samples to guide targeted treatment is widely used in clinical practice, and is recommended by expert groups for many tumor types and biomarkers. [11,12] The classical approach to IHC scoring for biomarkers, such as human epidermal growth factor receptor-2 (HER2), classifies specimens as either ‘positive’ or ‘negative’, scoring samples as IHC0, 1+, 2+ or 3+ per pathologists’ visual interpretation. [11,12]

Read more

Diagnosis and management of pancreatic neuroendocrine tumours

/0 Comments/in , , /by

In February 2025, Dr Shirley Liu (Department of Surgery, The Chinese University of Hong Kong) and Dr Shelly Ni (Department of Anatomical & Cellular Pathology, The Chinese University of Hong Kong) shared their experience and expertise on gastric neuroendocrine tumours (NETs).

Read more

Navigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker Assessment

/in , /by

Due to the availability of human epidermal growth factor receptor 2 (HER2)-directed therapies, testing for HER2 alterations, including overexpression, gene amplification or mutations is recommended in treatment guidelines for various tumor types, including breast cancer, gastric cancer, biliary tract cancer, cervical cancer, colorectal cancer, non-small cell lung cancer (NSCLC), and others.1-10

Read more
Endocrine/neuroendocrine tumours: The multidisciplinary team (MDT) for endocrine/neuroendocrine tumours

Surgical management and pathology of gastric neuroendocrine tumours

/0 Comments/in , , /by

In February 2025, Dr Shirley Liu (Department of Surgery, The Chinese University of Hong Kong) and Dr Shelly Ni (Department of Anatomical & Cellular Pathology, The Chinese University of Hong Kong) shared their experience and expertise on gastric neuroendocrine tumours (NETs).

Read more
Oncology European society for medical oncology (ESMO) annual meeting 2024: key developments in the treatment paradigm for metastatic colorectal cancer

European society for medical oncology (ESMO) annual meeting 2024: key developments in the treatment paradigm for metastatic colorectal cancer

/0 Comments/in /by
Read more
Role of netupitant/palonosetron in the management of Carboplatin-induced Nausea and Vomiting

Role of netupitant/palonosetron in the management of Carboplatin-induced Nausea and Vomiting

/Enter your password to view comments./in , , /by

There is no excerpt because this is a protected post.

Read more
MHK-FOS-2024019 Netupitant palonosetron in the Effective Management of Multiday Chemotherapy

Netupitant/palonosetron in the Effective Management of Multiday Chemotherapy-induced Nausea and Vomiting

/Enter your password to view comments./in , , /by

There is no excerpt because this is a protected post.

Read more
Advancements in aNSCLC Treatment Highlights from WCLC 2024

Advancements in aNSCLC Treatment: Highlights from WCLC 2024

/0 Comments/in , /by

Lung cancer continues to be a leading cause of cancer-related deaths in Hong Kong, with non-small cell lung cancer (NSCLC) accounting for about 82% of cases in 2021. Recent findings from the World Conference on Lung Cancer (WCLC) 2024, highlight promising advancements in the treatment of advanced NSCLC (aNSCLC).

Read more
Cervical Cancer Treatment and Prognosis: Revelations from ESMO 2024 Gynaecological Cancers Congress

Cervical Cancer Treatment and Prognosis: Revelations from ESMO 2024 Gynaecological Cancers Congress

/0 Comments/in /by

Cervical cancer (CC) is the 4th most common cancer in women worldwide, with approximately 660,000 new cases in 2022. In Hong Kong, it was the 7th most common cancer among women in 2021, with approximately 600 new cases and 178 deaths. Here we report new findings on CC treatment and prognostic methods from three abstracts published at the annual ESMO Gynaecological Cancer Congress, 20–22 June 2024, Florence, Italy.

Read more
Endocrine/neuroendocrine tumours: The multidisciplinary team (MDT) for endocrine/neuroendocrine tumours

The multidisciplinary team (MDT) for endocrine/neuroendocrine tumours

/0 Comments/in , , /by

The Prince of Wales Hospital (PWH), Kwong Wah Hospital (KWH), Our Lady of Maryknoll Hospital (OLMH) and United Christian Hospital (UCH) are equipped with an MDT including endocrinologists, oncologists, surgeons and other specialists with experience, expertise and commitment towards providing the best possible care for patients with such rare cancers.

Read more